Ionis, Otsuka's ALS subtype data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 23 September, 2026

September 28: Don Ingber of the Wyss Institute joins our Endpoints 11 virtual day for a fireside chat, alongside interviews with the honorees and gala highlights. Open to everyone, free to join. Register now.

presented by Every­body op­ti­mizes the first 20% of pa­tient re­cruit­ment. Tri­als fall apart in the oth­er 80%.

news Roche kidney drug's Phase 3 win sets up path to accelerated approval Novo's CEO knows the drugmaker needs to build confidence News Briefing Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal

Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

Endpoints Pharma Vertex aims for broad kidney disease label ahead of key readout next year US trade officials hear case on declining German drug prices Compounder Empower receives FDA warning letter over GLP-1s

in case you missed it 1. Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details 2. Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials 3. Viking touts once-a-month maintenance data for its weight loss candidate 4. Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes 5.